Half of Clinical Trial Management Professionals Share Critical Information via E-mail
IntraLinks Poll Shows
NEW YORK, Jan. 26, 2009—Fifty percent of clinical trial management professionals in the life sciences industry still share high-value, proprietary company information via e-mail, while others do so via fax (15 percent) or overnight courier (14 percent), according to a recent IntraLinks® poll.
Respondents who were considering web-based solutions for exchanging clinical trial information with outside parties indicated their primary concerns were security (40 percent), ease and flexibility of use (23 percent), speed of information sharing (17 percent), standardization across the enterprise (7 percent) and shipping/travel cost savings (7 percent).
In addition, respondents indicated that the greatest challenges they face when starting a new study or clinical trial are getting research sites onboard quickly (61 percent); reducing cycle time (22 percent); and exchanging information with all sites efficiently (12 percent).
“Executives may not realize that study start-up communication and management can be made simpler, faster and more secure by employing online solutions,” said Alison Shurell, vice president of life sciences product marketing for IntraLinks. “Using an online workspace enables sponsors, CROs, sites, IRBs and others in a clinical trial to exchange information instantaneously in the most secure environment available. Our life sciences clients who have shifted the clinical trial process to an online solution have reported tremendous improvements in overall productivity and efficiency.”
More than 50 executives from pharmaceutical, biotechnology, medical device and healthcare companies and CROs responded to polling questions for a recent webcast titled “Site Activation: How to Reduce Costs and Shorten Study Start-up Time.” Sixty three percent of the polling respondents are involved in the management of clinical trials for their companies.
Executives from Quintiles Transnational and Copernicus Group IRB presented during the webcast, reporting that they employ online workspace technology to expedite the exchange of critical information during clinical trials. Both organizations indicated that significant time and money savings have been realized as a result.
About IntraLinks
IntraLinks® On-Demand Workspaces£ connect business communities and accelerate the intelligent flow of information and documents among participants. Through IntraLinks' secure, neutral, online environments, companies are better able to compete globally by accelerating essential business processes, simplifying communication and fostering rapid workflow.
IntraLinks is easily accessible anywhere, anytime using a web browser. Since 1997, more than 750,000 participants representing over 90,000 organizations worldwide have used IntraLinks On-Demand Workspaces£ to communicate and collaborate on thousands of projects and transactions. IntraLinks has been adopted widely in the financial services and pharmaceutical industries, where its clients include AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank, FDIC, TD Securities, Thomas Weisel Partners and WestLB, among hundreds of others. Founded in 1996, IntraLinks is headquartered in New York with offices around the world. For more information, visit www.intralinks.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
2 Commerce Drive
Cranbury, NJ 08512